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Solute	carrier	family	1,	member	1	(SLC1A1;	also	known	as	EAAT3	and	EAAC1)	is	the	major	epithelial	trans-
porter	of	glutamate	and	aspartate	in	the	kidneys	and	intestines	of	rodents.	Within	the	brain,	SLC1A1	serves	as	
the	predominant	neuronal	glutamate	transporter	and	buffers	the	synaptic	release	of	the	excitatory	neurotrans-
mitter	glutamate	within	the	interneuronal	synaptic	cleft.	Recent	studies	have	also	revealed	that	polymorphisms	
in	SLC1A1	are	associated	with	obsessive-compulsive	disorder	(OCD)	in	early-onset	patient	cohorts.	Here	we	
report	that	SLC1A1	mutations	leading	to	substitution	of	arginine	to	tryptophan	at	position	445	(R445W)	and	
deletion	of	isoleucine	at	position	395	(I395del)	cause	human	dicarboxylic	aminoaciduria,	an	autosomal	reces-
sive	disorder	of	urinary	glutamate	and	aspartate	transport	that	can	be	associated	with	mental	retardation.	
These	mutations	of	conserved	residues	impeded	or	abrogated	glutamate	and	cysteine	transport	by	SLC1A1	
and	led	to	near-absent	surface	expression	in	a	canine	kidney	cell	line.	These	findings	provide	evidence	that	
SLC1A1	is	the	major	renal	transporter	of	glutamate	and	aspartate	in	humans	and	implicate	SLC1A1	in	the	
pathogenesis	of	some	neurological	disorders.
Introduction
Dicarboxylic aminoaciduria (DA; OMIM 222730) involves a 
striking excretion of urinary glutamate and aspartate, resulting 
from the incomplete reabsorption of anionic amino acids from 
the glomerular filtrate in the kidney. DA is an autosomal reces-
sive disorder with an estimated frequency of 1:36,000 (1), which 
was first described in 1974 (2). The clinical features of the disor-
der have not been widely explored, due to the paucity of clinical 
cases; however, of the 4 independent cases examined, 2 report an 
association with mental retardation (2, 3). Solute carrier family 1, 
member 1 (SLC1A1), also referred to in human studies as excit-
atory amino acid transporter 3 (EAAT3) or in rodents as excitatory 
amino acid carrier 1 (EAAC1), is a high-affinity anionic amino acid 
transporter expressed in the kidney, a wide variety of epithelial tis-
sues, brain, and eye. Convincing studies in rabbits and rodents 
have established that SLC1A1 plays a major role in the renal and 
intestinal transport of glutamate and aspartate (4–6). SLC1A1 is 
also found in neurons throughout the cortex, particularly in the 
hippocampus, basal ganglia, and the olfactory bulb (7), in which 
it is thought to be involved in facilitating γ-aminobutyric acid and 
glutathione biosynthesis (8, 9). SLC1A1 functions to buffer local 
glutamate concentrations at excitatory synapses in the hippo-
campus and modulates the differential recruitment of glutamate 
receptor subtypes at extrasynaptic sites (10). To date, no germline 
mutations in SLC1A1 have been functionally characterized.
The study of the genetics and pathophysiology of aminoac-
idurias have guided our understanding of epithelial transport 
physiology. Our group, through the Australian Aminoaciduria 
Consortium, and others have identified the genetic determi-
nants of 4 out of the 5 principal aminoacidurias (11), including 
cystinuria (OMIM #220100; type A SLC3A1, ref. 12, and type B 
SLC7A9, ref. 13); lysinuric protein intolerance (OMIM #222700; 
SLC7A7, refs. 14 and 15); Hartnup disorder (OMIM #234500; 
SLC6A19, refs. 16 and 17); and iminoglycinuria (OMIM #242600; 
SLC36A2 and SLC6A20, ref. 18). DA has until now remained with-
out a molecular explanation. Here we describe the first molecu-
lar characterization to our knowledge of human DA pedigrees. 
Affected family members inherited homozygous loss-of-function 
mutations (I395del and R445W) in SLC1A1. We demonstrate the 
potential pathogenic consequences of the mutations, using bio-
chemical analysis after Xenopus laevis oocyte expression and sub-
cellular localization studies.
Results
Probands were (proband 1) a 44-year-old Australian man with Ital-
ian ancestry and (proband 2) a 4-year-old girl of French-Canadian 
descent. Proband 1 presented with kidney stones at the age of 20, 
which also occurred in his brother at the same age. He was ini-
tially diagnosed with DA by urinary analysis, and persistent DA 
was confirmed at age 44 in this study. Proband 1 admitted to life-
long behavior comprising hand washing approximately 20 times 
per day and regularly rechecking the kitchen oven after leaving the 
house, both suggestive of an obsessive-compulsive trait. However, 
he declined formal psychological assessment for obsessive-com-
pulsive disorder (OCD). Proband 2 was diagnosed with DA at birth 
in the Quebec neonatal mass urinary screening program (1), and 
persistent DA was confirmed at age 4 in this study.
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2011;121(1):446–453. doi:10.1172/JCI44474.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 1   January 2011 447
In proband 1 (patient 1-II-1), we confirmed elevations in the uri-
nary glutamate and aspartate levels, with a urinary glutamate level 
of 1,377 μmol/mmol creatinine (normal range, 0–12 μmol/mmol 
creatinine) and an aspartate level of 46 μmol/mmol creatinine 
(normal range, 2–7 μmol/mmol creatinine), while all other urinary 
amino acid levels were normal (see Table 1). This pattern of urinary 
aminoaciduria confirmed the diagnosis of DA. His brother (patient 
1-II-2) was then screened and diagnosed at 40 years of age with DA, 
in light of isolated elevations in urinary glutamate and aspartate, 
with levels of 1,052 and 51 μmol/mmol creatinine, respectively. In 
proband 2 (patient 2-II-1), the urinary diagnosis for DA was con-
firmed at 4 years of age, with glutamate levels of 1,225 μmol/mmol 
creatinine (normal range, 0–63 μmol/mmol creatinine) and aspar-
tate levels of 50 μmol/mmol creatinine (normal range, 0–26 μmol/
mmol creatinine), with all other amino acids within their respective 
normal ranges. All other family members tested had urinary gluta-
mate and aspartate levels within normal ranges.
We sequenced the candidate gene SLC1A1, based on its estab-
lished role in glutamate and aspartate transport in rodents (6) 
and prior functional (19) and localization studies (5). All coding, 
untranslated, and regulatory regions of SLC1A1 were sequenced 
in genomic DNA from probands, including parents, siblings, and 
offspring (see Supplemental Table 1 for all primer sequences; sup-
plemental material available online with this article; doi:10.1172/
JCI44474DS1). In pedigree 1, a missense mutation, c.1333C > T, 
in exon 12 of SLC1A1 was found, resulting in an arginine to tryp-
tophan substitution at position 445 (p.R445W) (Figure 1A). Both 
affected siblings (patients 1-II-1 and 1-II-2) were homozygous for 
c.1333C > T, while all other family members were heterozygous 
(Table 2). In pedigree 2, a 3-bp deletion, c.1184–1186delTCA, was 
identified in exon 10 of SLC1A1, resulting in the deletion of iso-
leucine at position 395 (p.I395del) (Figure 1A). Proband 2 (patient 
2-II-1) was homozygous for the c.1184–1186delTCA mutation, 
while the parents were both heterozygous (Table 2). Mutant 
SLC1A1 alleles in all homozygotes were consistent with an autoso-
mal recessive inheritance pattern and segregated with the urinary 
phenotype. The inheritance of mutant alleles was independently 
confirmed by restriction fragment length polymorphism (RFLP) 
analysis in both pedigrees (Figure 1B). The c.1333C > T muta-
tion was detected through the inactivation of an AgeI site, and 
c.1184–1186delTCA was detected through the creation of a BsaBI 
site. A panel of 480 normal Australian genomic DNA samples and 
an additional panel of 95 genomic DNA samples from French-
Canadian subjects were subsequently screened by RFLP analysis 
to determine the allele frequency of both mutations. To the best 
of our knowledge, both mutations were novel and did not occur in 
their respective ethnically matched, normal populations. Interest-
ingly, both mutations in SLC1A1 lie within a 39-kb region at chro-
mosomal location 9p24 that has a significant association with 
OCD, based on a genome-wide linkage study (20), a replication 
study (21), and numerous family-based gene association studies 
(22–27) of early-onset OCD cohorts (summarized in Figure 1C).
Arginine 445, situated within transmembrane helix 8, is conserved 
in all known orthologs of SLC1A1 and within the 7 members of the 
SLC1 transporter family (Figure 2A). Isoleucine 395 is a conserved 
hydrophobic residue at identical positions in SLC1A1 orthologs 
and is the predominant residue in other SLC1 family members 
(Figure 2A). We mapped the predicted location of these residues, 
using the crystal structure of a prokaryotic glutamate transporter 
homolog from Pyrococcus horikoshii (GltPh) (28, 29). R445 was pre-
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dicted to be in close proximity to the substrate-binding pocket, and 
I395 was predicted to be in HP2, a hairpin loop structure that has 
been shown to act as an extracellular gate governing access of the 
substrate to the binding site (Figure 2B) (28, 29).
The functional effects of 
SLC1A1 mutations on substrate 
transport were examined in 
X. laevis oocytes. The addition of 
100 μM l-glutamate to oocytes 
injected with SLC1A1 WT com-
plementary RNA (cRNA) gener-
ated an inward current (Figure 
3A). This transport conductance 
decreased to 20% of that of WT 
in oocytes expressing SLC1A1 
R445W mutant cRNA and was 
abrogated in oocytes expressing 
SLC1A1 I395del mutant cRNA 
(Figure 3A). Furthermore, the 
addition of excess l-glutamate 
(1 mM) to oocytes expressing 
SLC1A1 I395del produced no 
transport current, similar to 
noninjected controls (Figure 
3A). Glutamate washout from 
the R445W mutant transporter 
was considerably slower than 
that from WT (see current 
traces in Figure 3A). In oocytes 
expressing WT SLC1A1, the sub-
strate concentration which elic-
its half the maximal transport 
current (K0.5) for l-glutamate 
was 30 ± 4 μM, while the K0.5 
of l-glutamate-generated cur-
rent for R445W was 2.0 ± 0.3 
μM (Figure 3B). This apparent 
increase in l-glutamate affinity 
and slower washout of gluta-
mate in R445W indicated that 
l-glutamate was more tightly 
bound compared with the WT 
transporter and may explain the 
reduced transporter currents 
observed. The rate of radiola-
beled glutamate uptake in WT- 
and R445W-expressing oocytes 
was examined at their respec-
tive K0.5 concentrations to accu-
rately represent differences in 
glutamate transport activity. At 
2 μM 3H-l-glutamate the R445W 
mutant exhibited glutamate 
flux levels that were 2% of those 
of WT (Figure 3C). Again, the 
level of glutamate uptake in the 
I395del mutant was equivalent 
to that of noninjected oocytes, 
indicating that this transporter 
was nonfunctional (Figure 3C). 
The highly conserved R445 residue is in close proximity to an 
arginine residue (R447) that has been shown to interact with the 
γ-carboxyl group of glutamate (30) and an aspartate residue 
(D444), which is important for transport (Figure 2A and ref. 31). 
Figure 1
DA pedigrees with mutations identified in SLC1A1. (A) Pedigrees consistent with autosomal recessive inheri-
tance are shown. Filled symbols represent individuals with DA, arrows indicate each proband, and the diago-
nal line represents a deceased subject. Representative chromatograms from control or DA pedigree DNA, 
with allele genotype (WT, wildtype; Mut, mutant) indicated. Boxes indicate the location of each mutation. (B) 
RFLP analysis of DA pedigrees. For c.1333C > T RFLP, AgeI digestion releases 252- and 229-bp fragments 
(shown as control [C]). The c.1333C > T mutation inactivates the AgeI site, leaving a 481-bp product (top 
panel). For c.1184–1186delTCA RFLP, BsaBI does not cut the 461-bp PCR product (shown as control). The 
c.1184-1186delTCA mutation results in a 458-bp amplicon, which is cut by BsaBI into 245- and 213-bp frag-
ments (bottom panel). L, 100-bp ladder. (C) The OCD-associated region at 9p24 containing SLC1A1. The 
39-kb region identified in early-onset OCD cohorts is represented by the red line; SLC1A1 coding regions are 
represented by gray bars; untranslated regions are represented by vertical white bars; blue shading indicates 
a significant association with OCD (P < 0.05); red shading indicates an experimentally validated loss-of-func-
tion mutation; stacked boxes represent SNPs; blue triangles represent markers linked to OCD; connected 
blue circles indicate haplotype blocks significantly associated with OCD (P < 0.05); lower boxes indicate 
missense mutations (c.490A > G [T164A, ref. 40]), c.1184–1186delTCA [I395del], c.1333C > T [R445W]); 
red arrow indicates an association with OCD-like features; and coordinates represent telomeric distance (in 
Mb). Sex-specific association with OCD is indicated (male [M] or female [F]). Roman numerals correlate with 
individual OCD studies: i (20); ii (21); iii (26); iv (27); v (25); vi (22); vii (23); and viii (24).
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We and others have previously shown that mutation of R445 in 
SLC1A1 to serine, methionine, or glutamine or the equivalent argi-
nine residue (R447) in SLC1A3 (EAAT1) to methionine results in 
low levels of glutamate flux and a large glutamate-activated leak 
cation conductance (32, 33). However, when R445 was mutated to 
the bulky, hydrophobic tryptophan residue present in pedigree 1, 
glutamate flux levels were similarly reduced, but there was no glu-
tamate-activated leak cation current (Supplemental Figure 1).
SLC1A1 is known to transport the glutathione precursor l-cys-
teine (34); however, subjects with DA do not hyperexcrete l-cyste-
ine or its endogenous oxidation product l-cystine. The K0.5 values 
for l-cysteine transport measured from WT- and R445W-express-
ing oocytes were 115 ± 13 μM and 3 ± 0.1 μM, respectively (Fig-
ure 3D). The increased affinity for l-cysteine resulting from the 
R445W mutation in SLC1A1 led to a reduction in 35S-l-cysteine 
uptake to levels that were 2% of those of WT, while I395del pre-
vented 35S-l-cysteine uptake by SLC1A1 (Figure 3E). Consequently, 
the increase in l-glutamate and l-cysteine affinity for R445W not 
only reduced the size of the transporter currents observed but also 
substantially reduced the rate of substrate transport. Complemen-
tary to these functional studies, analysis of the surface expression 
of EGFP-tagged SLC1A1 in oocytes was performed. WT SLC1A1 
was expressed uniformly on the oocyte surface (Figure 3F), while 
surface expression of the SLC1A1 R445W mutant was greatly 
reduced (Figure 3G). Surface expression was not observed in non-
injected oocytes (Figure 3H).
Expression studies were performed to ascertain whether these 
mutations also affected SLC1A1 surface expression in Madin-
Darby canine kidney (MDCKII) cells. In WT SLC1A1-expressing 
cells, expression was observed at the plasma membrane as well as 
in cytoplasmic reservoirs within the cell (Figure 4A) similar to that 
described in glioma cells (35). Introduction of the R445W muta-
tion greatly decreased expression overall, with low level or absent 
membrane staining observed (Figure 4B), similar to our observa-
tion in oocytes. We have shown reduced or minimal in vitro sur-
face expression of R445W, which would be the primary determi-
nant of reduced or minimal glutamate and cysteine uptake (Figure 
3G and Figure 4B). However, some residual surface expression of 
mutant SLC1A1 in vivo in humans may occur, and the reduced 
intrinsic impairment of transporter capacity (Figure 3, C and E) 
would further impair net substrate transport. The expression of 
the I395del mutant was negligible (Figure 4C) and similar to that 
of background levels (Figure 4D), supporting our evidence that the 
I395del mutation renders SLC1A1 nonfunctional.
In normal human kidney, SLC1A1 was distributed at the apical 
surface throughout the proximal tubule, including segment S1 
emerging from the glomerulus (Figure 4E) and later segments 
S2 and S3 (data not shown), consistent with previous analy-
sis in rodent kidney (5). The absence of apical staining in the 
peptide-blocked control confirmed antibody specificity (Figure 
4H). SLC1A1 also colocalized with Lotus tetragonolobus agglutinin 
(LTA) binding, the known apical marker of proximal tubules 
Table 2
Mutations identified in SLC1A1 in pedigrees with DA
Gene	 	 	 SLC1A1	
Locus	 	 	 9p24.2	
Allele	 	 	 c.1184–1186delTCA c.1333C > T
Mutation	 	 	 p.I395del p.R445W
	 Patient	 Phenotype	 	
 1-I-1 NM +/+ +/–
 1-II-1 DA +/+ –/–
 1-II-2 DA +/+ –/–
 1-III-1 NM +/+ +/–
 1-III-2 NM +/+ +/–
 2-I-1 NM +/– +/+
 2-I-2 NM +/– +/+
 2-II-1 DA –/– +/+
Each patient is listed with the phenotype (either DA or normal [NM]) 
and with the informative genotype obtained from sequencing SLC1A1 
(RefSeq NM_004170.4).
Figure 2
Mapping of the SLC1A1 mutations. (A) Highly conserved regions in 
orthologs of SLC1A1 (top group) and SLC1 family members (middle 
group) and the SLC1A1 consensus sequence (bottom). Residues I395 
and R445, deleted and mutated, respectively, in DA pedigrees are 
indicated. Residues known to be functionally important in SLC1A1, 
aspartate 444 (31) and arginine 447 (30), are indicated (diamonds). 
Blocks of the same color highlight groups of the same or similar 
amino acids: yellow, hydrophobic; red, acidic; orange, basic; purple, 
aromatic; blue, amido; green, hydroxyl; gray, proline; and pink, sul-
fur containing. (B) Predicted location of mutant residues based on 
the crystal structure of the prokaryotic glutamate transporter (GltPh). 
R445 (equivalent to M395 in GltPh) is predicted to be located in trans-
membrane 8, and I395 (equivalent to I339 in GltPh) is in hairpin loop 2 
(HP2) near the hinge region. Blue spheres indicate sodium ions; Asp 
represents the aspartate substrate.
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(Figure 4, F and G). Overall, the distribution of SLC1A1 was 
consistent with its major role in high-affinity glutamate reab-
sorption in the kidney. A summary of our findings is depicted 
in a model of the renal proximal tubule (Figure 5). The principle 
amino acid transporters involved in amino acid reabsorption, 
which have been identified by us and others, to be mutated in 
inherited human aminoacidurias are now all shown.
Discussion
Until now definitive proof of the involvement of SLC1A1 in human 
DA was lacking despite prior speculation (6, 36). We report 2 muta-
tions, a missense mutation, R445W, and a deletion, I395del, in the 
high-affinity glutamate transporter SLC1A1 from 2 independent 
pedigrees with DA. Our molecular and functional analyses of these 
SLC1A1 mutations provide evidence for their involvement in the 
pathogenesis of DA. First, both mutations segregated with the uri-
nary phenotype; second, they were not present in normal, ethni-
cally matched populations; third, they occurred in regions of 
SLC1A1 that are functionally important for substrate trans-
port; fourth, they nearly or fully abolished substrate trans-
port and cell surface expression; and fifth, the distribution of 
SLC1A1 in the proximal tubule was consistent with a prima-
ry role for high-affinity uptake of glutamate and aspartate 
in the human kidney. In subjects with no residual SLC1A1 
function an isolated DA was evident. These data establish 
that SLC1A1 is responsible for the majority, if not all, of 
renal glutamate and aspartate reabsorption. In contrast, the 
majority of renal cysteine transport occurs in the oxidized 
state as cystine, facilitated by a heterodimeric exchanger, 
comprising SLC3A1 and SLC7A9, and thus can still occur 
when SLC1A1 is inactivated. As is the case for renal autoso-
mal recessive disorders, such as Hartnup disorder (16, 17) 
and iminoglycinuria (18), one functional allele suffices to 
prevent urinary wastage of amino acids.
Our findings on SLC1A1 disruption in humans were in 
agreement with the DA phenotype reported in Slc1a1 nulli-
zygous mice (6). Despite this phenotypic similarity between 
species, the appearance of age-related neurodegeneration, which 
was observed in outbred Slc1a1 nullizygous mice (9), has not yet 
been clearly documented in humans. This neurodegeneration was 
attributed to decreased neuronal cysteine uptake (9). Cysteine is 
the rate-limiting substrate for the synthesis of glutathione, and 
neurons are dependent on the extracellular uptake of cysteine for 
normal function. Most cell types transport cysteine in the form of 
cystine, by heteroexchange with glutamate via the sodium-indepen-
dent system x–c (37), but in vitro studies suggest that neurons lose 
this capacity as they mature (38). Neurons use sodium-dependent 
cysteine uptake as the major route for cysteine uptake (80%–90% 
of total uptake), most of which is handled by SLC1A1 (75%–85% 
of total sodium-dependent uptake) (39). Thus, abrogation of cys-
teine uptake in the neurons of outbred Slc1a1 nullizygous mice led 
to impaired glutathione metabolism, increased oxidative stress, and 
neuronal death (9). However, in a separate study using Slc1a1 nulli-
zygous mice that were not fully backcrossed to the inbred C57BL/6 
Figure 3
Mutations in SLC1A1 from subjects with DA affect its function. 
(A) Representative oocytes expressing WT, R445W, or I395del 
cRNA or noninjected oocytes (control) were clamped at –60 mV 
and perfused with ND96 buffer containing 100 μM (for WT and 
R445W) or 1 mM (for I395del and control) l-glutamate. Black 
scale bars represent the time (s, x axis) that l-glutamate was 
applied and the current size (nA, y axis). Scale is shown for time 
versus current. (B) The l-glutamate dose response for WT (filled 
circles) and R445W (open circles). Current (Inorm) was normalized 
to the maximal current, defined as unit Imax (WT, K0.5 = 30 ± 4 
μM and Imax = 424 ± 13 nA; R445W, K0.5 = 2 ± 0.3 μM and Imax 
53 ± 7 nA). (C) Radiolabeled l-glutamate uptake at K0.5. (D) The 
l-cysteine dose response for WT (filled circles) and R445W 
(open circles). Current was normalized to the maximal cur-
rent (WT, K0.5 = 115 ± 13 μM and Imax = 590 ± 19 nA; R445W, 
K0.5 = 3.3 ± 0.1 μM and Imax = 54 ± 20 nA). (E) Radiolabeled 
l-cysteine uptake at K0.5. 3H-l-glutamate and 35S-l-cysteine uptake 
in noninjected oocytes was subtracted from the data presented 
(C and E, respectively). All data represent the mean ± SEM of at 
least 3 oocytes (in B–E). (F–H) Representative oocytes express-
ing EGFP-tagged SLC1A1 cRNA. (F) WT oocytes. (G) R445W 
oocytes. (H) Noninjected control oocytes. Scale bar: 200 μm.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 1   January 2011 451
strain (N4-N7), indicators of oxidative stress in young adult mice 
were not detected (10). This indicates that the genetic background 
of the Slc1a1 nullizygous mice will be important when interpreting 
any future neurological or behavioral studies. SLC1A1 function in 
renal epithelial cells is readily detected by urine analysis; however, 
evidence of reduced or absent SLC1A1 function in human neurons 
is more difficult to demonstrate.
Neurological dysfunction such as mental retardation has been 
associated with DA in 2 independent clinical reports (2, 3); however, 
due to the small number of clinically evaluable individuals with 
DA and the potential age-related onset of symptoms, neurological 
assessment has been difficult. Intriguingly, proband 1 in pedigree 1 
exhibited features consistent with a diagnosis of OCD, but he 
declined formal psychological assessment for OCD. This observa-
tion is interesting in light of the strong association between SLC1A1 
and OCD, as revealed by genome-wide linkage (20), replication (21), 
and family-based association studies (22–27) of early-onset OCD 
cohorts in which a genetic contribution to disease etiology is likely. 
Furthermore, 5 out of 6 family-based gene association studies 
showed a significant association of polymorphisms or haplotypes 
in SLC1A1 to early-onset OCD in males. OCD is characterized by 
increased behavioral and cognitive rigidity and a loss of executive 
control over actions as well as dysfunction in associated neural cir-
cuitry. Slc1a1 nullizygous mice have not yet been thoroughly exam-
ined for executive dysfunction phenotypical of OCD. To date, only 
one rare variant, c.490A > G (p.T164A), in a conserved region of 
SLC1A1 has been identified in OCD cohorts (40), though this has 
not been functionally tested. A molecular explanation for a role for 
SLC1A1 in OCD may yet lie in noncoding regions within or imme-
diately adjacent to the SLC1A1 locus.
In this report we have demonstrated that recessive mutations 
in SLC1A1 lead to DA. This discovery provides what we believe to 
be the only known human examples for the loss of function of 
SLC1A1 and demonstrates its major role in renal glutamate and 
aspartate handling in humans. The extent of glutamate and cys-
teine transport non-redundancy in neurons due to mutations in 
SLC1A1 in human DA patients, and therefore neurological dys-
function, may entirely depend on the degree of loss of function and 
patient age. Neurodegeneration may result only when SLC1A1-
mediated cysteine transport is fully abrogated, as observed in 
Slc1a1 nullizygous mice. The same SLC1A1-mediated defect in 
renal glutamate transport may provoke abnormal neuronal func-
tion in a subset of patients with DA.
Methods
Sample collection and analysis. Institutional ethics committee approval was 
obtained for all studies in humans (University of Sherbrooke Health Cen-
tre, 05-005 and 05-005R, and Sydney South West Area Health Service, X04-
0239 and X06-0172). All adult subjects provided written informed consent, 
and for proband 2, informed consent was obtained from both parents. 
Quantitative urinary amino acid analysis of morning urine samples was 
performed by ion exchange chromatography, as we have described (18, 41). 
DNA was isolated from saliva samples collected using self-collection kits 
(DNAgenotek) or from peripheral blood mononuclear cells (PBMCs) iso-
lated by Ficoll density gradient centrifugation. PBMCs were immortalized 
by Epstein-Barr virus transformation, as we have described (17). The panel 
of Australian control genomic DNA samples (18) was isolated from blood 
samples from 480 deidentified individuals collected during routine test-
ing. The panel of 95 French-Canadian control DNAs represents a group of 
patients collected for the purpose of association studies in various neuro-
Figure 4
Tissue and subcellular distribution of SLC1A1. (A–D) Immunofluorescence of hemagglutinin epitope-tagged WT and mutant cDNAs stably 
expressed in MDCKII cells (A) SLC1A1 WT, (B) SLC1A1 R445W, and (C) SLC1A1 I395del MDCKII, and (D) empty vector (pcDNA3.1-HA). Scale 
bar: 10 μm. (E–H) Immunofluorescence of normal adult human kidney, showing SLC1A1 expression in proximal tubules. Kidney sections were 
stained with an SLC1A1 antibody (red) and the proximal tubule marker LTA (green). Nuclei were stained with DAPI (blue). (E) SLC1A1 expression 
on the apical membrane of kidney tubules. An example of an S1 segment (arrow) emerging from the glomerulus (g) is indicated. (F) LTA staining 
identifying the apical membrane of proximal tubules. (G) Colocalization (yellow) of SLC1A1 and LTA on the apical membrane of S1 segments of 
the proximal tubule (confocal images in E and F were merged). (H) Peptide-blocked control. A glomerulus is indicated. Scale bar: 30 μm.
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logical disorders (obtained from Jean-Baptiste Rivière and Guy Rouleau, 
University of Montreal, Montreal, Quebec, Canada). They have an average 
age of 60, are all from the Quebec province, and the 4 grandparents of each 
individual were all born in Quebec. A neurologist has examined them all, 
and no apparent neurological disorder was observed.
Molecular analysis. Nucleotide coordinates for the SLC1A1 mutations were 
taken from the RefSeq mRNA sequence for SLC1A1 (NM_004170.4). SLC1A1 
c.1184–1186delTCA (p.I395del) was identified by a RFLP resulting from 
the creation of a BsaBI restriction enzyme site, and c.1333C > T (p.R445W) 
was determined by an RFLP resulting from inactivation of an 
AgeI restriction enzyme site (see Supplemental Table 1 for primer 
sequences). The SLC1A1 cDNA was amplified using RT-PCR from 
human kidney mRNA (BD Biosciences) or from mRNA isolated 
from immortalized PBMCs from proband 1 and cloned into pGEM-
T-Easy (Promega). The SLC1A1 open reading frame was PCR ampli-
fied from pGEM-T-SLC1A1 as a 1,793-bp product incorporating 
EcoRI ends and then cloned into the mammalian expression vector 
pcDNA3.1-HA (18) for N-terminal hemagglutinin epitope tagging. 
The R445W mutant was excised from pGEM-T-SLC1A1(R445W) 
with BstEII/AflII and ligated into pcDNA3.1-HA-SLC1A1. The 
I395del mutation was synthesized as a 424-bp fragment compris-
ing c.924–1350, incorporating the c.1184–1186delTCA deletion, 
and provided in the pJ201 plasmid (DNA2.0). A 410-bp BsiWI/
AgeI fragment containing the I395del mutation was ligated into 
pcDNA3.1-HA-SLC1A1. For functional studies in X. laevis oocytes, 
SLC1A1 was PCR amplified with KpnI/BamHI ends and ligated into 
the oocyte expression vector pOTV (19) cut with KpnI/BglII. I395del 
and R445W mutant vectors were constructed by cloning the 410-bp 
BsiWI/AgeI I395del fragment and a 213-bp AccI R445W fragment 
into pOTV-SLC1A1, respectively. For surface expression in oocytes, 
EGFP was fused to the C terminus of SLC1A1. All protein sequenc-
es used in alignments were obtained from Ensembl release 57 and 
aligned using the ClustalW algorithm. Where sequence identity was 
50% or greater, the conserved residue was indicated.
Functional analysis. Radiolabeled glutamate and cysteine uptake 
and electrophysiological studies were performed in X. laevis 
oocytes after injection of in vitro–transcribed cRNA as previously 
described (34, 42, 43). Substrate uptake was measured by placing 
5 oocytes in ND96 buffer containing 3H-l-glutamate (GE Health-
care) or 35S-l-cysteine (Perkin Elmer). 35S-l-cysteine was stored 
at –80°C in 5 mM DTT under nitrogen, and all solutions were 
freshly prepared prior to use to minimize oxidation of cysteine.
Subcellular localization and tissue staining. Immunofluorescence of 
pcDNA3.1-HA-SLC1A1–transfected MDCKII cells and deidenti-
fied normal human kidney samples was performed as previously 
described (18). SLC1A1 expression was detected with a polyclonal 
goat anti-SLC1A1 antibody (1:10; sc-7761, Santa Cruz Biotechnol-
ogy Inc.) raised against a peptide corresponding to the C terminus 
(sc-7761P, Santa Cruz Biotechnology Inc.) and a donkey anti-goat 
Alexa Fluor 594 (1:400; Invitrogen). Proximal tubules were marked 
using the biotinylated lectin LTA (1:100; Vector Laboratories) and 
detected with streptavidin–Alexa Fluor 488 (Invitrogen). All anti-
bodies were diluted in PBS. Digital immunofluorescence images of 
cell and tissue staining were obtained with identical gain settings 
using a ×40 oil objective installed on a Leica SP5 confocal micro-
scope, using the 405-nm and 561-nm lasers. Oocytes expressing 
EGFP-tagged SLC1A1 were imaged live with a ×10 air objective 
using the 405-nm laser. All image series were equally processed 
using Canvas X (ACD Systems International).
Statistics. All functional studies in Xenopus oocytes were assessed 
using 2-way ANOVA. Mutant transporter activity in all cases was signifi-
cantly different to that of WT (P < 0.001).
Acknowledgments
Financial support was provided by the Australian National Health 
and Medical Research Council (NHMRC; project grant 402730), 
the Australian Research Council (Discovery Project DP0877897), 
University of Sydney Bridging Support Grant (RIMS 2009-02579), 
the Rebecca L. Cooper Foundation, and Cure The Future Founda-
Figure 5
A model of the renal proximal tubule, illustrating the principal epithelial transport-
ers involved in amino acid reabsorption, which are mutated in human aminoacid-
urias. A nephron is depicted (inset), showing the glomerulus, proximal convoluted 
tubule (PCT), proximal straight tubule (PST), distal convoluted tubule (DCT), and 
collecting duct (CD). A cross-section of the proximal convoluted tubule (white 
square indicated with an arrow) is represented in the main diagram. Four of the 
aminoacidurias, including DA, iminoglycinuria, Hartnup disorder, and cystinuria 
manifest at the apical surface of the renal tubule, while lysinuric protein intoler-
ance manifests at the basolateral surface. Mutations in the high-affinity glutamate 
and aspartate transporter SLC1A1, responsible for DA, were identified in this 
study. Iminoglycinuria results from complete inactivation of SLC36A2, a proline 
and glycine transporter, or from additional modifying mutations in the high-affinity 
proline transporter SLC6A20 when SLC36A2 is not completely inactivated (18). 
Mutations in the neutral amino acid transporter, SLC6A19, are responsible for 
Hartnup disorder (16, 17). The neutral amino acid transport defect can also be 
exacerbated by a kidney-specific loss of heterodimerization of mutant SLC6A19 
with TMEM27 (44). Cystinuria has a heterogeneous phenotype and arises from 
mutations in individual or both subunits of the disulfide bridge-linked heterodi-
mer comprising the type II membrane protein SLC3A1 (12) and the cystine and 
basic amino acid transporter SLC7A9 (13). Lysinuric protein intolerance (14, 15) 
results from mutations in the basolaterally expressed basic amino acid transport-
er SLC7A7, which forms a disulfide bridge-linked heterodimer with type II mem-
brane protein SLC3A2. The major transporters involved in each aminoaciduria 
are in bold. For a detailed review of renal epithelial amino acid transport systems 
and their involvement in disease see Bröer (45).
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 1   January 2011 453
tion. R.M. Ryan is supported by an NHMRC Career Development 
Award, and R.J. Vandenberg is supported by an NHMRC Senior 
Research Fellowship. Assistance in clinical amino acid quantita-
tion was provided by Robert Giguère from the Biochemical Genet-
ics Service, Centre Hospitalier Université de Sherbrooke and Kevin 
Carpenter of the New South Wales Biochemical Genetics and New-
born Screening Services at The Children’s Hospital at Westmead. 
We thank Mairwen Jones for helpful discussions, Cheryl Handford 
for assistance in oocyte preparation, Angelika Bröer for oocyte 
transport assays, and Jean-Baptiste Rivière and Guy Rouleau of 
the Centre of Excellence in Neuromics, University of Montreal, for 
normal, French-Canadian human genomic DNA samples.
Received for publication July 22, 2010, and accepted in revised 
form October 20, 2010.
Address correspondence to: John E.J. Rasko, Centenary Institute, 
Locked Bag No. 6, Newtown 2042, New South Wales, Austra-
lia. Phone: 61.2.95656156; Fax: 61.2.95656101; E-mail: j.rasko@ 
centenary.org.au.
 1. Auray-Blais C, Cyr D, Drouin R. Quebec neonatal 
mass urinary screening programme: from micromol-
ecules to macromolecules. J Inherit Metab Dis. 2007; 
30(4):515–521.
 2. Teijema HL, van Gelderen HH, Giesberts MA, Lau-
rent de Angulo MS. Dicarboxylic aminoaciduria: an 
inborn error of glutamate and aspartate transport 
with metabolic implications, in combination with a 
hyperprolinemia. Metabolism. 1974;23(2):115–123.
 3. Swarna M, Rao DN, Reddy PP. Dicarboxylic amino-
aciduria associated with mental retardation. Hum 
Genet. 1989;82(3):299–300.
 4. Kanai Y, Hediger MA. Primary structure and func-
tional characterization of a high-affinity glutamate 
transporter. Nature. 1992;360(6403):467–471.
 5. Shayakul C, Kanai Y, Lee WS, Brown D, Rothstein 
JD, Hediger MA. Localization of the high-affinity 
glutamate transporter EAAC1 in rat kidney. Am J 
Physiol. 1997;273(6 pt 2):F1023–F1029.
 6. Peghini P, Janzen J, Stoffel W. Glutamate transporter 
EAAC-1-deficient mice develop dicarboxylic amino-
aciduria and behavioral abnormalities but no neuro-
degeneration. EMBO J. 1997;16(13):3822–3832.
 7. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, 
Kuncl RW. Selective loss of glial glutamate trans-
porter GLT-1 in amyotrophic lateral sclerosis. Ann 
Neurol. 1995;38(1):73–84.
 8. Nieoullon A, Canolle B, Masmejean F, Guillet B, 
Pisano P, Lortet S. The neuronal excitatory amino 
acid transporter EAAC1/EAAT3: does it represent 
a major actor at the brain excitatory synapse? J Neu-
rochem. 2006;98(4):1007–1018.
 9. Aoyama K, et al. Neuronal glutathione deficiency 
and age-dependent neurodegeneration in the EAAC1 
deficient mouse. Nat Neurosci. 2006;9(1):119–126.
 10. Scimemi A, Tian H, Diamond JS. Neuronal trans-
porters regulate glutamate clearance, NMDA recep-
tor activation, and synaptic plasticity in the hippo-
campus. J Neurosci. 2009;29(46):14581–14595.
 11. Camargo SM, Bockenhauer D, Kleta R. Aminoac-
idurias: Clinical and molecular aspects. Kidney Int. 
2008;73(8):918–925.
 12. Calonge MJ, et al. Cystinuria caused by mutations 
in rBAT, a gene involved in the transport of cystine. 
Nat Genet. 1994;6(4):420–425.
 13. Feliubadaló L, et al. Non-type I cystinuria caused by 
mutations in SLC7A9, encoding a subunit (bo,+AT) 
of rBAT. Nat Genet. 1999;23(1):52–57.
 14. Torrents D, et al. Identification of SLC7A7, encod-
ing y+LAT-1, as the lysinuric protein intolerance 
gene. Nat Genet. 1999;21(3):293–296.
 15. Borsani G, et al. SLC7A7, encoding a putative 
permease-related protein, is mutated in patients 
with lysinuric protein intolerance. Nat Genet. 1999; 
21(3):297–301.
 16. Kleta R, et al. Mutations in SLC6A19, encoding 
B0AT1, cause Hartnup disorder. Nat Genet. 2004; 
36(9):999–1002.
 17. Seow HF, et al. Hartnup disorder is caused by 
mutations in the gene encoding the neutral 
amino acid transporter SLC6A19. Nat Genet. 2004; 
36(9):1003–1007.
 18. Bröer S, et al. Iminoglycinuria and hyperglycinuria 
are discrete human phenotypes resulting from 
complex mutations in proline and glycine trans-
porters. J Clin Invest. 2008;118(12):3881–3892.
 19. Arriza JL, Fairman WA, Wadiche JI, Murdoch 
GH, Kavanaugh MP, Amara SG. Functional com-
parisons of three glutamate transporter subtypes 
cloned from human motor cortex. J Neurosci. 1994; 
14(9):5559–5569.
 20. Hanna GL, et al. Genome-wide linkage analysis of 
families with obsessive-compulsive disorder ascer-
tained through pediatric probands. Am J Med Genet. 
2002;114(5):541–552.
 21. Willour VL, et al. Replication study supports evi-
dence for linkage to 9p24 in obsessive-compulsive 
disorder. Am J Hum Genet. 2004;75(3):508–513.
 22. Shugart YY, et al. A family-based association study 
of the glutamate transporter gene SLC1A1 in obses-
sive-compulsive disorder in 378 families. Am J Med 
Genet B Neuropsychiatr Genet. 2009;150B(6):886–892.
 23. Wendland JR, et al. A haplotype containing quan-
titative trait loci for SLC1A1 gene expression and 
its association with obsessive-compulsive disorder. 
Arch Gen Psychiatry. 2009;66(4):408–416.
 24. Kwon JS, et al. Association of the glutamate trans-
porter gene SLC1A1 with atypical antipsychotics-
induced obsessive-compulsive symptoms. Arch Gen 
Psychiatry. 2009;66(11):1233–1241.
 25. Stewart SE, et al. Association of the SLC1A1 glu-
tamate transporter gene and obsessive-compulsive 
disorder. Am J Med Genet B Neuropsychiatr Genet. 
2007;144B(8):1027–1033.
 26. Dickel DE, et al. Association testing of the position-
al and functional candidate gene SLC1A1/EAAC1 
in early-onset obsessive-compulsive disorder. Arch 
Gen Psychiatry. 2006;63(7):778–785.
 27. Arnold PD, Sicard T, Burroughs E, Richter MA, 
Kennedy JL. Glutamate transporter gene SLC1A1 
associated with obsessive-compulsive disorder. 
Arch Gen Psychiatry. 2006;63(7):769–776.
 28. Boudker O, Ryan RM, Yernool D, Shimamoto K, 
Gouaux E. Coupling substrate and ion binding to 
extracellular gate of a sodium-dependent aspartate 
transporter. Nature. 2007;445(7126):387–393.
 29. Yernool D, Boudker O, Jin Y, Gouaux E. Structure of 
a glutamate transporter homologue from Pyrococ-
cus horikoshii. Nature. 2004;431(7010):811–818.
 30. Bendahan A, Armon A, Madani N, Kavanaugh MP, 
Kanner BI. Arginine 447 plays a pivotal role in sub-
strate interactions in a neuronal glutamate trans-
porter. J Biol Chem. 2000;275(48):37436–37442.
 31. Teichman S, Kanner BI. Aspartate-444 is essential for 
productive substrate interactions in a neuronal gluta-
mate transporter. J Gen Physiol. 2007;129(6):527–539.
 32. Ryan RM, Kortt NC, Sirivanta T, Vandenberg RJ. 
The position of an arginine residue influences 
substrate affinity and K(+) coupling in the human 
glutamate transporter, EAAT1. J Neurochem. 2010; 
114(2):565–575.
 33. Borre L, Kanner BI. Arginine 445 controls the 
coupling between glutamate and cations in the 
neuronal transporter EAAC-1. J Biol Chem. 2004; 
279(4):2513–2519.
 34. Zerangue N, Kavanaugh MP. Interaction of L-cys-
teine with a human excitatory amino acid trans-
porter. J Physiol. 1996;493(pt 2):419–423.
 35. Fournier KM, González MI, Robinson MB. Rapid 
trafficking of the neuronal glutamate transporter, 
EAAC1: evidence for distinct trafficking pathways 
differentially regulated by protein kinase C and 
platelet-derived growth factor. J Biol Chem. 2004; 
279(33):34505–34513.
 36. Smith CP, Weremowicz S, Kanai Y, Stelzner M, 
Morton CC, Hediger MA. Assignment of the gene 
coding for the human high-affinity glutamate 
transporter EAAC1 to 9p24: potential role in dicar-
boxylic aminoaciduria and neurodegenerative dis-
orders. Genomics. 1994;20(2):335–336.
 37. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. 
Glutathione metabolism and its implications for 
health. J Nutr. 2004;134(3):489–492.
 38. Murphy TH, Schnaar RL, Coyle JT. Immature corti-
cal neurons are uniquely sensitive to glutamate tox-
icity by inhibition of cystine uptake. FASEB J. 1990; 
4(6):1624–1633.
 39. Shanker G, Allen JW, Mutkus LA, Aschner M. The 
uptake of cysteine in cultured primary astrocytes 
and neurons. Brain Res. 2001;902(2):156–163.
 40. Wang Y, et al. A screen of SLC1A1 for OCD-related 
alleles. Am J Med Genet B Neuropsychiatr Genet. 2010; 
153B(2):675–679.
 41. Auray-Blais C, Giguère R, Lemieux B. Newborn 
urine screening programme in the province of Que-
bec: an update of 30 years’ experience. J Inherit Metab 
Dis. 2003;26(4):393–402.
 42. Huang S, Ryan RM, Vandenberg RJ. The role of 
cation binding in determining substrate selectiv-
ity of glutamate transporters. J Biol Chem. 2009; 
284(7):4510–4515.
 43. Ryan RM, Mitrovic AD, Vandenberg RJ. Site-direct-
ed mutagenesis in the study of membrane trans-
porters. Methods Mol Biol. 2003;227:97–108.
 44. Kowalczuk S, Bröer A, Tietze N, Vanslambrouck 
JM, Rasko JE, Bröer S. A protein complex in the 
brush-border membrane explains a Hartnup disor-
der allele. FASEB J. 2008;22(8):2880–2887.
 45. Broer S. Amino acid transport across mammalian 
intestinal and renal epithelia. Physiological Reviews. 
2008;88(1):249–286.
